At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
ENMD-2076drug
Likely dose
ENMD-2076 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)
In Brief
A Phase 2 clinical trial evaluating ENMD-2076 for Advanced Adult Hepatocellular Carcinoma and Advanced Fibrolamellar Carcinoma. Completed, enrolled 35 participants across 5 sites.
Detailed Summary
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC. Safety will be measured by looking at the adverse events that may happen and the efficacy will look at the progression of the disease over time.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartOct 2015
Primary CompletionJun 2018
TodayJul 2026
First PostedSep 9, 2014
Enrollment StartOct 1, 2015
Primary CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.8 years ago
Interventions
ENMD-2076drug
250 mg oral dose, once daily (QD) for 28 day cycles